Moneycontrol PRO
HomeAuthorRavi ananthanarayanan

Ravi Ananthanarayanan

Executive Editor - MC Pro

Moneycontrol

Comment | China’s surprise recovery lends a shine to metal stocks

BUSINESS

Comment | China’s surprise recovery lends a shine to metal stocks

China's surprise upturn in manufacturing activity is good news for the global economy and more particularly for Indian metal stocks

Comment | Sebi’s puzzling U-turn on minority oversight over royalty, and a bullet for it to bite

COMPANIES

Comment | Sebi’s puzzling U-turn on minority oversight over royalty, and a bullet for it to bite

At the last minute Sebi has deferred a rule that would have made companies seek minority shareholders' permission to pay royalty. What that means and how it could make it better

HCC turns claims to cash, gets some breathing space

COMPANIES

HCC turns claims to cash, gets some breathing space

HCC's innovative move to convert claims to cash will help lower some of its debt but it has some way to go before investors can rest easy

Comment | Elections may serve a bitter harvest to UP sugar mills

BUSINESS

Comment | Elections may serve a bitter harvest to UP sugar mills

Investors in UP sugar mill stocks should be watchful, as politicians trade barbs on unpaid sugarcane dues to farmers

Opinion | Jet Airways: Why IBC may have been the right stick after all

BUSINESS

Opinion | Jet Airways: Why IBC may have been the right stick after all

The insolvency process may be the best option to get shareholders of a defaulting company to co-operate in a rescue bid with lenders

Comment | GST and real estate: Government goes the extra mile

COMPANIES

Comment | GST and real estate: Government goes the extra mile

The revised structure and rules do seem to make it more beneficial for builders and takes care of some of their concern

Lupin and peers run into US FDA headwinds again

COMPANIES

Lupin and peers run into US FDA headwinds again

Lupin’s shares fell after an FDA inspection led to its US unit being issued an adverse warning. Other pharma companies too have tripped on inspections, raising fears that compliance issues are very much alive for the industry

Comment | Nestle: royalty to stay at 4.5%, free cash flow rises

COMPANIES

Comment | Nestle: royalty to stay at 4.5%, free cash flow rises

Nestle decides to keep its royalty constant at 4.5%. That will be a relief for investors who were fearing an increase. Its 2018 annual report shows that cash flows are rising and are healthy but working capital is showing some strain

Comment | NCLT’s ArcelorMittal-Essar Steel order: critical loose ends remain

SECTOR

Comment | NCLT’s ArcelorMittal-Essar Steel order: critical loose ends remain

NCLT order on ArcelorMittal’s resolution plan for Essar Steel highlights dependence on Essar Group’s infrastructure and seeks continued access. Also cites Wednesbury Principle to ask for a more equitable distribution to all creditors.

Comment | Copper uptrend supports an EM bull case, barring one risk factor

BUSINESS

Comment | Copper uptrend supports an EM bull case, barring one risk factor

Copper’s rise supports a bull case for EM equities but these forecasts rest on one country not upsetting the apple cart

Comment | ArcelorMittal - Essar Steel: winners, losers and the in-betweens

BUSINESS

Comment | ArcelorMittal - Essar Steel: winners, losers and the in-betweens

ArcelorMittal’s resolution plan for Essar Steel is set to bring the curtains down on a high profile case in the insolvency process. Who won, who lost?

ArcelorMittal’s Essar Steel acquisition: an 800-pound gorilla enters the market

BUSINESS

ArcelorMittal’s Essar Steel acquisition: an 800-pound gorilla enters the market

ArcelorMittal's acquisition of Essar Steel is a risk for domestic steel producers, as the global giant gets a ready asset in one of the largest and fastest growing markets for steel in the world

Comment | Cipla takes a calculated risk with generic Sensipar launch

BUSINESS

Comment | Cipla takes a calculated risk with generic Sensipar launch

Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk

Comment | US FDA to get a new chief, watch for side effects on pharma shares

BUSINESS

Comment | US FDA to get a new chief, watch for side effects on pharma shares

The US FDA has been driving generic drug approvals under its current commissioner. His resignation raises a question mark on whether life could change for Indian pharmaceutical companies

Comment | The rise and rise of Patanjali in oral care

BUSINESS

Comment | The rise and rise of Patanjali in oral care

Patanjali’s threat has been downplayed by the Street in recent years, as its performance has faltered and its competitive streak appears more subdued. Don’t write it off just yet, says the data

Comment | Sugar loans: a soft touch to clear cane arrears

BUSINESS

Comment | Sugar loans: a soft touch to clear cane arrears

The government’s decision to give subsidized loans to sugar mills is designed to solve the politically sensitive issue of cane arrears in the run-up to elections

Comment | Merck’s dividend gift is extra special for P&G

BUSINESS

Comment | Merck’s dividend gift is extra special for P&G

Merck’s Rs440 a share special dividend is good news for investors but more so for its new parent P&G. After the dividend, life for investors will return to mundane things such as performance-driven valuations

Comment | Real estate GST rate cuts don’t go far enough

BUSINESS

Comment | Real estate GST rate cuts don’t go far enough

Investors were looking forward to a cut in GST on under-construction properties, to spur real estate sector growth. What the government gave with one hand, the other took away

Comment | The Baltic Dry Index is capsizing

BUSINESS

Comment | The Baltic Dry Index is capsizing

The Baltic Dry Index has fallen sharply after the Vale dam incident in 2019 and also due to global developments that have affected trade

Comment | Dr Copper signals an improving economic outlook in 2019

BUSINESS

Comment | Dr Copper signals an improving economic outlook in 2019

Copper prices have risen sharply in 2019 partly due to tight supply conditions. It may also be a pointer to improving economic conditions

Dr Reddy’s Suboxone launch: Why investors shrugged it off

BUSINESS

Dr Reddy’s Suboxone launch: Why investors shrugged it off

Dr Reddy’s generic Suboxone launch is set to be a reality. A much-awaited event, a mounting threat from competitors may limit its benefits

Comment | Sugar minimum price: small carrot, big stick

BUSINESS

Comment | Sugar minimum price: small carrot, big stick

The increase of Rs 2 per kg in the minimum selling price of sugar is much less than what the industry wanted but even this comes with strings attached. The government wants cane arrears cleared.

100-Word Take | Dr Reddy's: Slipping on familiar ground

BUSINESS

100-Word Take | Dr Reddy's: Slipping on familiar ground

Dr Reddy’s investors baulked after news that an inspection by the US FDA found four repeat observations.

Comment | Bhushan Power adds heft to JSW Steel, deal structure holds the key

BUSINESS

Comment | Bhushan Power adds heft to JSW Steel, deal structure holds the key

Bhushan Power adds to JSW Steel’s domestic capacity but will the latter settle for a minority stake again?

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347